Biotech Values

[poorgradstudent]

GTHX:

88% ORR and 1 CR in 17 pts in 1st line SCLC is impressive.

Is it? From the tables I've put together, trends in ORR 1st line SCLC for their backbone regimen started in the mid 40s and have moved into the 70%+ range (see the recent tarextumab data). Given the small numbers in the G1T28 trial, I don't have confidence that their result is truly an indication of efficacy... call it the IDO Uncertainty Principle.

Other factors add to my skepticism:

- They said that they would be able to increase dose intensity of the chemo due to the protective action of G1T28. The data to date does not back that up.

- Historically, the promise of similar efficacy with reduced AEs is a very tough road when your backbone regimen is a chemo. Uncertainty for an approval path (from my view) is a big negative.

Again, these are just my views on the data to date. More data may prove my view misguided.